文献速递头颈部肿瘤放疗姑息放疗与转移瘤

淋巴结阳性皮肤头颈部鳞癌的治疗总时长研究

Treatment Package Time in Node-Positive Cutaneous Head and Neck Squamous Cell Carcinoma.
PubMed 文献 · Pract Radiat Oncol · 2019-10-10

该单中心回顾性研究纳入2001至2014年接受根治性手术及术后放疗的152例淋巴结阳性皮肤头颈部鳞癌患者,评估治疗总时长(TPT)对生存和局控的影响。多变量分析显示TPT≥14周与更差的总生存、疾病特异性生存、无进展生存及无局部区域失败生存显著相关,且延迟启动术后放疗是TPT延长的主要原因。

要点

  • TPT≥14周与淋巴结阳性cHNSCC患者更差的OS、CSS、PFS和FFLRF独立相关。
  • 免疫抑制和≥2个病理阳性淋巴结也是OS和FFLRF的显著不良因素。
  • 延迟启动PORT而非治疗中断是TPT延长的主因,应及时转诊和开始PORT。

核心结论

  • TPT延长至14周或以上可能降低淋巴结阳性cHNSCC患者接受手术和PORT后的局部区域控制率和生存率。

研究设计与样本

  • 单中心回顾性研究,纳入2001至2014年接受根治性手术(宏观肿瘤清除)后标准分割PORT的淋巴结阳性cHNSCC患者152例。

主要发现

  • 5年OS为62%(95%CI 54-71),CSS为78%(95%CI 71-87),PFS为54%(95%CI 46-64),FFLRF为76%(95%CI 68-85)。
  • 多变量模型中,TPT≥14周与更差OS(HR 4.93;95%CI 2.54-9.56;P<.001)、CSS(HR 6.09;95%CI 2.33-15.92;P=.001)、PFS(HR 4.29;95%CI 2.21-8.34;P<.001)和FFLRF(HR 4.63;95%CI 1.71-12.51;P=.007)相关。
  • 免疫抑制和≥2个病理阳性淋巴结是OS和FFLRF的显著不良因素,包膜外延伸也与更低的FFLRF相关。
  • 延迟启动PORT而非治疗中断是TPT延长的主要原因。

临床怎么用

  • 对淋巴结阳性cHNSCC术后患者,应优化流程及时转诊并尽早启动PORT,避免TPT延长至14周或以上。
  • 关注免疫抑制状态和阳性淋巴结数目≥2个等高危因素,加强局控和生存监测。

局限性

  • 单中心回顾性研究,样本量152例,可能存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Treatment package time (TPT) prolongation is associated with lower overall survival and locoregional control in mucosal head and neck squamous cell carcinoma (SCC), but there are few reports in cutaneous HNSCC (cHNSCC). We sought to test the effect of TPT in a cohort of patients with cHNSCC. METHODS: This is a single institution retrospective study of node-positive cHNSCC patients involving either the parotid or cervical nodes treated with curative intent surgery with macroscopic tumor clearance followed by standard fractionation postoperative radiation therapy (PORT) from 2001 to 2014. We assessed the effect of TPT and other prognostic variables on overall survival (OS), cHNSCC specific survival (CSS) progression free survival (PFS), and freedom from locoregional failure (FFLRF). RESULTS: In the present study, 152 patients met the inclusion criteria. The 5-year OS, CSS, PFS, and FFLRF were 62% (95% confidence interval [CI], 54-71), 78% (95% CI, 71-87), 54% (95% CI, 46-64), and 76% (95% CI ,68-85), respectively. In a multivariable model, TPT ≥14 weeks was associated with worse outcomes in all endpoints (OS [hazard ratio (HR) 4.93; 95% CI, 2.54-9.56, P < .001], CSS [HR 6.09; 95% CI, 2.33-15.92; P = .001], PFS [HR 4.29; 95% CI, 2.21-8.34; P < .001], and FFLRF [HR 4.63; 95% CI, 1.71-12.51; P = .007]). Immunosuppression and the presence of ≥2 pathologically involved lymph nodes were also significant adverse factors for both OS and FFLRF, although extracapsular extension was also associated with lower FFRLF. Delays to commencing PORT rather than treatment breaks accounted for the majority of cases with prolonged TPT. CONCLUSIONS: Prolongation of TPT to 14 weeks or longer may confer a lower probability of locoregional control and survival in patients with lymph node-positive cHNSCC treated with surgery and PORT. Timely referral and commencement of PORT is necessary to maximize long-term disease outcomes.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Daniels CP, Bressel M, Corry J, et al. Treatment Package Time in Node-Positive Cutaneous Head and Neck Squamous Cell Carcinoma. Pract Radiat Oncol. 2019. PMID: 31606546. doi:10.1016/j.prro.2019.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。